EQ

1.0605.36%
CM

Charles McDermott

Independent Director

Mr. Charles McDermott, also known as Charlie, served as Chairman of the Board at Anavo Therapeutics BV since December 2021. He served as an Entrepreneur in Residence at Omega Fund Management, LLC. He joined Omega Funds in January 2019. He served as a Director at Impact Biomedicines, Inc. He served as Chief Business Officer and President at Impact Biomedicines, Inc. from September 2017 to May 2018. He serves as President and Chief Executive Officer at Primmune Therapeutics, Inc. since March 2019 and served as its Chairman since March 2019 until 2024. Mr. McDermott served as President of Kala Pharmaceuticals, Inc., from June 2015 to August 7, 2017 and served as its Chief Business Officer from October 2014 to August 7, 2017. Previously, Mr. McDermott served Interim President at Kala Pharmaceuticals, Inc., from October 2014 to June 2015 and served as its Executive Vice President of Business Development since June 2013 until October 2014. Mr. McDermott was responsible for leading and executing business development strategy for Kala's Mucosal Penetrating Product (MPP) technology platform as it continues to generate novel topical product candidates and to advance its lead ophthalmic candidates towards first in man clinical studies. He serves as a Director at Equillium, Inc. since September 2018. Mr. McDermott has operating experience in the biotechnology, ophthalmology and life sciences industry. He has held roles of increasing responsibility in drug discovery, regulatory affairs, corporate development, commercial planning and executive management. He also currently serves as Director at Primmune Therapeutics. He has taken on positions of increasing responsibility in drug discovery, regulatory affairs and business development. He served as Vice President of Global Business Development for the Eye Care and Drug Delivery business units at Allergan. He served at Allergan. He was focused on eye care and drug delivery opportunities. Mr. McDermott completed a variety of transactions and partnerships that involved novel platforms (DARPins, PEMs, siRNA, etc.) to commercial products such as Acular (TM), Acuvail (TM), Latisse (TM) and Lastacaft (TM). Prior to joining Allergan, Mr. McDermott held an Associate Director of Business Development positions at deCODE Genetics where he had responsibility for growing and integrating service and platform technology businesses. Before that, he worked at Pfizer/Agouron in drug discovery and regulatory affairs. Mr. McDermott began his career as a research scientist within the angiogenesis pharmacology group at Agouron Pharmaceuticals where he championed the concept of testing potential cancer treatments for angiogenic diseases of the eye. Mr. McDermott earned his MBA in Finance, Entreprenuership and Marketing at the University of San Diego from 2000 to 2004, an MA degree in Molecular, Cellular and Developmental Biology at the University of California at Santa Barbara and a BA degree in Biochemistry and Molecular Biology from the University of California Santa Cruz.

Positions